The Alabama Court of Civil Appeals rejected the Alabama Medical Cannabis Commission's (AMCC) attempt to dismiss a lawsuit filed by a medical marijuana operator, challenging its already troubled medical cannabis licensing process.
What Happened
Jemmstone Alabama, LLC, filed the lawsuit in December 2023, alleging mismanagement and improper denial of its application for an integrated medical cannabis facility license, reported Alabama Political Reporter.
In the lawsuit, Jemmstone initially named AMCC only as a defendant, in the caption of the complaint. However, throughout the document, the plaintiff consistently referenced individual commissioners.
The AMCC sought to take advantage of this procedural detail, insisting the absence of commissioners from the caption made the complaint invalid under the Alabama Rules of Civil Procedure.
The commission argued that the lawsuit should be dismissed on jurisdictional grounds, claiming sovereign immunity.
The appellate court ruled that the omission of commissioners’ names from the caption was a technical error, rejecting AMCC's claim of sovereign immunity and allowing the lawsuit to proceed.
The court also rejected the AMCC’s claim that improper service of process made the case invalid.
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
What's Next
The case now proceeds in the Montgomery Circuit Court.
The medical marijuana program was legalized in 2021 in Alabama. However, its implementation has been postponed due to ongoing legal challenges.
So far, AMCC managed to award, but not issue licenses to businesses that have applied to enter the state's medical market.
In December 2023, the Alabama cannabis regulator awarded 20 medical cannabis licenses for the production, distribution, dispensing and testing of medical marijuana (MMJ) as well as five of the most coveted permits – the integrated facility licenses, which allow for vertical integration. This move came after several failed attempts to allocate licenses.
Read Next:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.